| IL1α | IL1β | IL1ra | IL6 | |
| Normal | Not detected | 3.8 (2.2–4.0) | 755 (165–1212) | 0.3 (0–0.5) |
| WG all patients | 58.9 (0–84.9)† | 13.21 (4.0–41.5)# | 4957 (1453–36 819)† | 2.3 (1.0–16.8)† |
| WG pathogen present | 28.1 (0–77.7) | 5.0 (4.0–38.5) | 5,824 (4085–45 175)* | 3.5 (2.1–15.7) |
| WG no pathogen | 84.6 (38.11) | 4.0 (4.0–50.6) | 3307 (1112–11 275) | 1.8 (1.3–16.8) |
| IPF all patients | 33.7 (0–50.0) | 0.5 (0.5–23.9) | 8061 (1450–22 104)† | 8.4 (3.5–17.4)† |
| IPF pathogen present | 36.5 (0–74.5) | 10.3 (0.5–36.9) | 22,104 (2890–33 978)* | 13.4 (6.0–22.1) |
| IPF no pathogen | 18.9 (0–21.6) | 1.0 (0.5–5.0) | 3008 (628–8002) | 3.5 (2.7–12.9) |
Measurements are expressed at pg/ml concentration. Levels are expressed as median (interquartile range).
*Statistically significant difference between pathogen present and pathogen not present. †Statistically significant difference between disease group and normal controls.
IL, interleukin; IL1ra, interleukin1 receptor antagonist; IPF, idiopathic pulmonary fibrosis; WG, Wegener granulomatosis.